Published in Ther Adv Vaccines on March 01, 2014
A fresh perspective from immunologists and vaccine researchers: Active vaccination strategies to prevent and reverse Alzheimer's disease. Alzheimers Dement (2015) 0.89
Immunogenicity and safety of different schedules of 2-dose varicella vaccination in China. Hum Vaccin Immunother (2016) 0.83
Seropositivity of Varicella zoster virus in vaccinated Korean children and MAV vaccine group. Hum Vaccin Immunother (2016) 0.79
Varicella-zoster virus seroprevalence in children and adolescents in the pre-varicella vaccine era, Germany. BMC Infect Dis (2017) 0.78
Prevention of Herpes Zoster and its complications: from clinical evidence to real life experience. Hum Vaccin Immunother (2016) 0.75
Integration of hepatitis B vaccination into national immunisation programmes. Viral Hepatitis Prevention Board. BMJ (1997) 5.10
Clinical practice. Herpes zoster. N Engl J Med (2002) 4.72
Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep (2007) 4.60
Loss of vaccine-induced immunity to varicella over time. N Engl J Med (2007) 4.55
Decline in mortality due to varicella after implementation of varicella vaccination in the United States. N Engl J Med (2005) 3.83
Deaths from chickenpox in England and Wales 1995-7: analysis of routine mortality data. BMJ (2001) 3.81
Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. JAMA (2002) 3.59
Shift in age in chickenpox. Lancet (1992) 3.59
Live vaccine used to prevent the spread of varicella in children in hospital. Lancet (1974) 3.24
Varicella-zoster virus. Clin Microbiol Rev (1996) 3.03
Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect (2001) 2.98
Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992-2002. J Infect Dis (2005) 2.74
Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatr Infect Dis J (2004) 2.69
Modification of chicken pox in family contacts by administration of gamma globulin. N Engl J Med (1962) 2.64
Intrauterine infection with varicella-zoster virus after maternal varicella. N Engl J Med (1986) 2.63
Effectiveness over time of varicella vaccine. JAMA (2004) 2.52
Stress-induced subclinical reactivation of varicella zoster virus in astronauts. J Med Virol (2004) 2.51
Shift in age in chickenpox. Lancet (1993) 2.46
Consequences of varicella and herpes zoster in pregnancy: prospective study of 1739 cases. Lancet (1994) 2.43
Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. Pediatrics (2010) 2.39
Impact of varicella vaccination on health care utilization. JAMA (2005) 2.38
Seroprevalence of varicella zoster virus infections in Colombo district, Sri Lanka. Indian J Med Sci (2007) 2.38
Evidence of increasing frequency of herpes zoster management in Australian general practice since the introduction of a varicella vaccine. Med J Aust (2010) 2.25
The epidemiology of varicella and its complications. J Infect Dis (1995) 2.10
Prevention of varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention. MMWR Recomm Rep (1996) 2.09
The age of infection with varicella-zoster virus in St Lucia, West Indies. Epidemiol Infect (1993) 2.07
Modelling the impact of immunization on the epidemiology of varicella zoster virus. Epidemiol Infect (2000) 1.95
Disseminated varicella infection due to the vaccine strain of varicella-zoster virus, in a patient with a novel deficiency in natural killer T cells. J Infect Dis (2003) 1.91
Herpes zoster incidence among insured persons in the United States, 1993-2006: evaluation of impact of varicella vaccination. Clin Infect Dis (2011) 1.89
Varicella vaccine effectiveness in the US vaccination program: a review. J Infect Dis (2008) 1.81
Changing varicella epidemiology in active surveillance sites--United States, 1995-2005. J Infect Dis (2008) 1.77
Varicella mortality: trends before vaccine licensure in the United States, 1970-1994. J Infect Dis (2000) 1.76
Varicella vaccines. WHO position paper. Wkly Epidemiol Rec (1998) 1.75
Review of varicella zoster seroepidemiology in India and Southeast Asia. Trop Med Int Health (1998) 1.75
Asymptomatic reactivation and shed of infectious varicella zoster virus in astronauts. J Med Virol (2008) 1.71
Herpes zoster-related hospitalizations and expenditures before and after introduction of the varicella vaccine in the United States. Infect Control Hosp Epidemiol (2008) 1.71
Severe complications of varicella in previously healthy children in Germany: a 1-year survey. Pediatrics (2001) 1.67
The comparative sero-epidemiology of varicella zoster virus in 11 countries in the European region. Vaccine (2007) 1.66
Live attenuated varicella vaccine. Efficacy for children with leukemia in remission. JAMA (1984) 1.65
Varicella vaccination in Europe - taking the practical approach. BMC Med (2009) 1.63
Hospitalizations for varicella in the United States, 1988 to 1999. Pediatr Infect Dis J (2002) 1.63
Herpes zoster in Australia: evidence of increase in incidence in adults attributable to varicella immunization? Epidemiol Infect (2010) 1.62
Varicella among adults: data from an active surveillance project, 1995-2005. J Infect Dis (2008) 1.60
Adolescent vaccination: coverage achieved by ages 13-15 years, and vaccinations received as recommended during ages 11-12 years, National Health Interview Survey 1997-2003. J Adolesc Health (2008) 1.60
The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998-2003. BMC Public Health (2005) 1.57
Preventing varicella-zoster disease. Clin Microbiol Rev (2005) 1.55
The burden of varicella complications before the introduction of routine varicella vaccination in Germany. Pediatr Infect Dis J (2008) 1.52
Effect of climatic factors and population density on varicella zoster virus epidemiology within a tropical country. Am J Trop Med Hyg (2001) 1.50
Development of resistance to acyclovir during chronic infection with the Oka vaccine strain of varicella-zoster virus, in an immunosuppressed child. J Infect Dis (2003) 1.50
Decline in varicella-related hospitalizations and expenditures for children and adults after introduction of varicella vaccine in the United States. Pediatrics (2004) 1.48
Impact of varicella vaccine on varicella-zoster virus dynamics. Clin Microbiol Rev (2010) 1.47
Near elimination of varicella deaths in the US after implementation of the vaccination program. Pediatrics (2011) 1.46
Effectiveness of 2 doses of varicella vaccine in children. J Infect Dis (2011) 1.45
Quantitation of varicella-zoster virus DNA in patients with Ramsay Hunt syndrome and zoster sine herpete. J Clin Microbiol (2001) 1.45
Increasing incidence of herpes zoster among Veterans. Clin Infect Dis (2010) 1.39
The incidence and clinical characteristics of herpes zoster among children and adolescents after implementation of varicella vaccination. Pediatr Infect Dis J (2009) 1.37
Latent and lytic infection of isolated guinea pig enteric ganglia by varicella zoster virus. J Med Virol (2003) 1.34
Population-based incidence of herpes zoster after introduction of a publicly funded varicella vaccination program. Vaccine (2011) 1.31
Clinical and subclinical reactivations of varicella-zoster virus in immunocompromised patients. J Infect Dis (1986) 1.28
Subclinical varicella-zoster virus viremia, herpes zoster, and T lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation. J Infect Dis (1992) 1.26
Impact of the routine varicella vaccination programme on varicella epidemiology in Germany. Euro Surveill (2010) 1.25
Antibody assays suitable for assessing immune responses to live varicella vaccine. Vaccine (1991) 1.22
Prevention of varicella: recommendations for use of varicella vaccines in children, including a recommendation for a routine 2-dose varicella immunization schedule. Pediatrics (2007) 1.20
Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting. Vaccine (2009) 1.20
Safety of varicella vaccine after licensure in the United States: experience from reports to the vaccine adverse event reporting system, 1995-2005. J Infect Dis (2008) 1.18
Costs and benefits of routine varicella vaccination in German children. J Infect Dis (1996) 1.17
VZV T cell-mediated immunity. Curr Top Microbiol Immunol (2010) 1.17
Persistence of varicella zoster virus DNA in saliva after herpes zoster. J Infect Dis (2011) 1.17
Long-term effectiveness of varicella vaccine: a 14-Year, prospective cohort study. Pediatrics (2013) 1.17
Use and limitations of varicella-zoster virus-specific serological testing to evaluate breakthrough disease in vaccinees and to screen for susceptibility to varicella. J Infect Dis (2008) 1.17
Epidemiology of varicella hospitalizations in the United States, 1995-2005. J Infect Dis (2008) 1.15
Prospective surveillance of hospitalisations associated with varicella-zoster virus infections in children and adolescents. Eur J Pediatr (2005) 1.14
Adult susceptibility to varicella in the tropics is a rural phenomenon due to the lack of previous exposure. J Infect Dis (1998) 1.14
Influence of age and nature of primary infection on varicella-zoster virus-specific cell-mediated immune responses. J Infect Dis (2010) 1.14
Peripheral blood mononuclear cells of the elderly contain varicella-zoster virus DNA. J Infect Dis (1992) 1.12
Younger age at vaccination may increase risk of varicella vaccine failure. J Infect Dis (2002) 1.11
Perspectives on vaccines against varicella-zoster virus infections. Curr Top Microbiol Immunol (2010) 1.11
Varicella in non-immune persons: incidence, hospitalization and mortality rates. Epidemiol Infect (2002) 1.11
Empirical data on the varicella situation in Germany for vaccination decisions. Clin Microbiol Infect (2004) 1.11
Cost-effectiveness of varicella vaccination programs: an update of the literature. Expert Rev Vaccines (2008) 1.10
Comparison of quantitations of viral load in varicella and zoster. J Clin Microbiol (2000) 1.10
Community impact of childhood varicella infections. J Pediatr (1997) 1.08
The cost-effectiveness of varicella vaccination in Canada. Vaccine (2002) 1.07
A phase I-II study of live attenuated varicella-zoster virus vaccine to boost immunity in human immunodeficiency virus-infected children with previous varicella. Pediatr Infect Dis J (2009) 1.06
Primary versus secondary failure after varicella vaccination: implications for interval between 2 doses. Pediatr Infect Dis J (2013) 1.04
The effect of funded varicella immunization programs on varicella-related hospitalizations in IMPACT centers, Canada, 2000-2008. Pediatr Infect Dis J (2012) 1.04
Decline in varicella-related ambulatory visits and hospitalizations in the United States since routine immunization against varicella. Pediatr Infect Dis J (2010) 1.04
Modeling the impact of one- and two-dose varicella vaccination on the epidemiology of varicella and zoster. Vaccine (2010) 1.03
Universal varicella vaccination in the Sicilian paediatric population: rapid uptake of the vaccination programme and morbidity trends over five years. Euro Surveill (2009) 1.03
Airborne transmission of nosocomial varicella from localized zoster. J Infect Dis (1988) 1.02
Impact of universal varicella vaccination on 1-year-olds in Uruguay: 1997-2005. Arch Dis Child (2008) 1.01
Epidemiology of chickenpox in France (1991-1995). J Epidemiol Community Health (1998) 1.01
Incidence of herpes zoster among children vaccinated with varicella vaccine in a prepaid health care plan in the United States, 2002-2008. Pediatr Infect Dis J (2009) 1.01
A cost benefit analysis of routine varicella vaccination in Spain. Vaccine (1999) 1.01
Progress in VZV vaccination? Some concerns. Med Microbiol Immunol (2013) 1.00
Herpes zoster in Germany: quantifying the burden of disease. BMC Infect Dis (2011) 0.99
Economic evaluation of varicella vaccination in Italian children and adolescents according to different intervention strategies: the burden of uncomplicated hospitalised cases. Vaccine (2008) 0.99
Social epidemiology of chickenpox in two British national cohorts. J Epidemiol Community Health (1993) 0.98
The value of varicella vaccination in healthy children: cost-benefit analysis of the situation in France. Vaccine (1999) 0.98
The cost-effectiveness of varicella vaccine programs for Australia. Vaccine (1999) 0.96